Study of AZD0466 monotherapy or in combination in patients with advanced haematological malignancies

Trial Identifier: D8241C00001
Sponsor: AstraZeneca
NCTID:: NCT04865419
Start Date: June 2021
Primary Completion Date: October 2024
Study Completion Date: October 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, 3004
AU Parkville, AU, 3050
DE Aachen, DE, 52074
DE Berlin, DE, 13353
DE Frankfurt, DE, 60590
DE Hannover, DE, 30625
DE Heidelberg, DE, 69120
DE Kiel, DE, 24105
FR Le Mans Cedex, FR, 72037
FR Pessac, FR, 33604
FR Toulouse, FR, 31059
IT Bologna, IT, 40138
IT Meldola, IT, 47014
IT Rome, IT, 00168
IT Rozzano, IT, 20089
KR Busan, KR, 47392
KR Seoul, KR, 03080
KR Seoul, KR, 06351
KR Seoul, KR, 6591
US, AZ Scottsdale, AZ, US, 85259
US, CA Duarte, CA, US, 91010
US, FL Jacksonville, FL, US, 32224
US, FL Miami, FL, US, 33136
US, FL Tampa, FL, US, 33612
US, GA Atlanta, GA, US, 30322
US, IL Chicago, IL, US, 60611
US, IL Chicago, IL, US, 60612
US, Illinois Chicago, Illinois, US, 60637
US, MA Boston, MA, US, 02114
US, MI Ann Arbor, MI, US, 48109
US, MN Rochester, MN, US, 55905
US, NE Omaha, NE, US, 68105
US, NY New York, NY, US, 10021
US, OH Columbus, OH, US, 43210
US, OR Portland, OR, US, 97239
US, TX Houston, TX, US, 77030
US, WI Milwaukee, WI, US, 53226